Abeona Therapeutics Inc vs Equinix Inc — how do they compare? Abeona Therapeutics Inc trades at $7.4 (market cap $424.33M), while Equinix Inc trades at $1,032.41 (market cap $102.95B). The key difference: Equinix Inc is far larger — about 242.6× Abeona Therapeutics Inc's market cap, and Equinix Inc pays a 1.98% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | EQIX | |
|---|---|---|
Market Cap | $424.33M | $102.95B |
Sector | Health | Real Estate |
52-Week High | $7.45 | $1.12K |
52-Week Low | $4.17 | $726.09 |
Enterprise Value | $279.23M | $124.08B |
Dividend Yield | — | 1.98% |
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.24, up 4.93% today, with bullish technical signals from moving averages. The company shows exceptional profitability with 454.86% net income margin and 70.99% ROE, though revenue remains modest at $5.82M. Recent developments include CMS granting NTAP status for ZEVASKYN and expansion to seven treatment centers, while Q2 2026 earnings are scheduled for August 13, 2026.
Strong analyst support (66.7% buy ratings) and attractive valuation metrics (P/E 7.84, EV/EBITDA 3.8) support upside potential, but negative operating cash flow and shareholder investigation pose near-term risks. The stock's outlook depends on commercial execution and Q2 earnings results.
Equinix (EQIX) trades at $1,042.62, down 0.97% on the day, with strong analyst support (74.5% buy ratings) and a consensus price target of $1,120. The stock shows bullish technical signals with support at $1,040 and resistance at $1,067. Recent Q2 2026 earnings beat expectations with $4.83 EPS versus $4.73 expected, while revenue growth continues at 9.2B in 2025 with improving net margins to 15.63%. The company maintains robust cash flow from operations at $3.9B despite significant capital investments.
EQIX presents a compelling growth story driven by AI infrastructure demand and global digital expansion, though elevated valuation multiples (P/E 67.09) and substantial debt levels ($15.2B total debt) warrant caution. The stock offers dividend income with recent $5.16 payments, but investors should monitor execution risks in capital-intensive expansion and competitive pressures in the data center REIT sector.
Trailing returns across standard periods
Latest headlines on both assets
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →Equinix is a retail provider of data centers, enabling hundreds of enterprise tenants to house their servers and networking equipment in a collocated environment. Tenants can then connect with each other, through cloud service providers and telecom networks. Equinix operates 240 data centers in 66 markets worldwide and owns just less than half of them. The firm has roughly 10,000 customers, including 2,000 networks, that are dispersed over five verticals: Cloud and IT Services, Content Providers, Network and Mobile Services, Financial Services, and Enterprise. About 70% of Equinix's revenue comes from renting space to tenants and related services, and more than 15% comes from connecting customers with each other. Equinix operates as a real estate investment trust.
Read more on EQIX →